SCI Pharmtech (Taiwan) Performance
| 4119 Stock | TWD 84.20 0.20 0.24% |
The firm has a beta of 0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, SCI Pharmtech's returns are expected to increase less than the market. However, during the bear market, the loss of holding SCI Pharmtech is expected to be smaller as well. At this point, SCI Pharmtech has a negative expected return of -0.086%. Please make sure to validate SCI Pharmtech's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if SCI Pharmtech performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SCI Pharmtech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, SCI Pharmtech is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 633 M | |
| Total Cashflows From Investing Activities | -539.6 M |
SCI |
SCI Pharmtech Relative Risk vs. Return Landscape
If you would invest 8,930 in SCI Pharmtech on October 22, 2024 and sell it today you would lose (510.00) from holding SCI Pharmtech or give up 5.71% of portfolio value over 90 days. SCI Pharmtech is generating negative expected returns and assumes 1.0854% volatility on return distribution over the 90 days horizon. Simply put, 9% of stocks are less volatile than SCI, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SCI Pharmtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SCI Pharmtech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SCI Pharmtech, and traders can use it to determine the average amount a SCI Pharmtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0792
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4119 |
Estimated Market Risk
| 1.09 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SCI Pharmtech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SCI Pharmtech by adding SCI Pharmtech to a well-diversified portfolio.
SCI Pharmtech Fundamentals Growth
SCI Stock prices reflect investors' perceptions of the future prospects and financial health of SCI Pharmtech, and SCI Pharmtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SCI Stock performance.
| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 9.19 B | |||
| Shares Outstanding | 95.38 M | |||
| Price To Earning | 14.98 X | |||
| Price To Book | 2.62 X | |||
| Price To Sales | 11.33 X | |||
| Revenue | 864.22 M | |||
| EBITDA | 129.25 M | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 12.73 X | |||
| Total Debt | 3.65 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 37.30 X | |||
| Cash Flow From Operations | 280.28 M | |||
| Earnings Per Share | 2.13 X | |||
| Total Asset | 4.19 B | |||
| Retained Earnings | 809 M | |||
| Current Asset | 1.8 B | |||
| Current Liabilities | 782 M | |||
About SCI Pharmtech Performance
Evaluating SCI Pharmtech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SCI Pharmtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SCI Pharmtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and specialty chemicals in Taiwan. SCI Pharmtech, Inc. was founded in 1987 and is based in Taoyuan City, Taiwan. SCI PHARMTECH operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about SCI Pharmtech performance evaluation
Checking the ongoing alerts about SCI Pharmtech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SCI Pharmtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SCI Pharmtech generated a negative expected return over the last 90 days | |
| About 49.0% of the company shares are owned by insiders or employees |
- Analyzing SCI Pharmtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SCI Pharmtech's stock is overvalued or undervalued compared to its peers.
- Examining SCI Pharmtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SCI Pharmtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SCI Pharmtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SCI Pharmtech's stock. These opinions can provide insight into SCI Pharmtech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.